drugset / Trial / NCT01521962
Study of Combination Therapy With SYR-322
RandomizedParallel-group
Summary
To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.
Timeline
- Start
- 2012-02
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Comparator | Insulin | Protein / enzyme biologic | — | Other |